

[54] **ENRICHED PLASMA DERIVATIVE FOR  
ADVANCEMENT OF WOUND CLOSURE  
AND HEALING**

[75] Inventor: Michael Stroetmann, Münster, Fed.  
Rep. of Germany

[73] Assignee: Serapharm Michael Stroetmann,  
Münster, Fed. Rep. of Germany

[21] Appl. No.: 385,664

[22] Filed: Jun. 7, 1982

[30] **Foreign Application Priority Data**

Jun. 25, 1981 [DE] Fed. Rep. of Germany ..... 3124962  
Dec. 18, 1981 [EP] European Pat. Off. .... 81110615

[51] Int. Cl.<sup>3</sup> ..... A61K 9/14; A61K 35/14;  
A61K 37/00

[52] U.S. Cl. .... 424/46; 424/45;  
424/101; 424/177

[58] Field of Search ..... 424/101, 177, 45, 46

[56] **References Cited**

**U.S. PATENT DOCUMENTS**

2,492,458 12/1949 Bering ..... 424/101  
4,298,598 11/1981 Schwarz et al. .... 424/177  
4,362,567 12/1982 Schwarz ..... 424/101

**OTHER PUBLICATIONS**

McKendrick—Chem. Abst., vol. 76 (1972), p. 17809n.  
Bruhn et al.—Chem. Abst., vol. 90 (1979), p. 101085v.  
Schwarz et al.—Chem. Abst., vol. 94 (1981), p. 36384h.  
Schwarz et al.—Chem. Abst., vol. 94 (1981), p. 36318q.

*Primary Examiner*—Sam Rosen

*Attorney, Agent, or Firm*—Gordon W. Hueschen

[57] **ABSTRACT**

A preparation for accelerated hemostasis and optimized biochemical control of wound closure ("tissue adhesive") consists only of solid, powdery, biologically active constituents and contains 60 to 96% by weight of fibrinogen, which is largely liberated from cryo-insoluble globulin, 0.05 to 5% by weight of a fibrinolysis inhibitor, and 0.1 to 15% by weight of thrombin and/or prothrombin. For use, this enriched plasma derivative may be applied in the form of a dry, powdery mixture immediately and directly onto the wound or in the area of operation, respectively. Further application methods provide atomizing, spraying, or foaming of the powdery mixture by means of a propellant.

**13 Claims, No Drawings**